Annual Report

Riding a wave of strong financial performance, Knowles Corp. prepares to outline its future in Medtech, Defense, and Industrial markets to investors.

Mobile game maker DarkIris pivots to an AI-first strategy, launching an R&D hub in Singapore to build a pan-entertainment AGI content platform.

China's EdTech giant TAL is set to report Q4 earnings. Investors are watching closely to see if its pivot to AI and smart devices is a winning strategy.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

Beasley Broadcast Group reports a staggering $190M Q4 loss after a massive asset write-down, but a major debt cut and digital growth signal a fight for survival.

XPeng reports an 80% monthly sales jump but a yearly decline, while launching a major strategic expansion into Mexico and Latin America.

A one-time gain gave the micro-cap a profitable quarter, but rising costs and reliance on a single large asset raise questions about its long-term stability.

Interlink Electronics reports a wider Q4 loss but makes key moves in autonomous vehicle and robotic surgery sensors, signaling a major strategic pivot.

The Texas fuel supplier is preparing a Nasdaq/NYSE move, banking on high energy prices from the Iran War to bolster its financials for the ambitious jump.

Tencent Music posts record profits and a huge dividend, but a shrinking user base and a new policy to hide key metrics leave investors wary.

As Argan prepares its Q4 results, investors are watching if its record backlog and dual energy strategy can sustain its powerful year-end performance.

UiPath reports its first-ever annual profit and a new $500M buyback, but its strategic pivot to agentic AI faces scrutiny over slowing growth.

After a 39% stock crash, Lakeland Industries' former CFO is sued over allegedly misleading investors about the company's deteriorating financial health.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

Automotive SaaS firm MotorK posts a dramatic financial turnaround, achieving positive cash flow in H2 2025 by leveraging AI and a bold customer strategy.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?

Colombia's energy giant is set to reveal its 2025 performance, testing its diversification strategy against falling oil prices and high investor expectations.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.